HSV-2 | |||||||||
---|---|---|---|---|---|---|---|---|---|
Men | Women | Total | |||||||
Baseline prevalence % (95% CI) | Follow-up prevalence % (95% CI) | Incidence per 1000 person-years (95% CI) | Baseline prevalence % (95% CI) | Follow-up prevalence % (95% CI) | Incidence per 1000 person-years (95% CI) | Baseline prevalence % (95% CI) | Follow-up prevalence % (95% CI) | Incidence per 1000 person-years (95% CI) | |
Rural | 3.82 (3.17 to 4.57) | 14.62 (13.09 to 16.28) | 23.3 (20.6 to 26.3) | 5.25 (4.49 to 6.12) | 23.17 (21.25 to 25.21) | 39.2 (35.6 to 43.0) | 4.54 (4.03 to 5.10) | 18.94 (17.82 to 20.11) | 31.1 (28.8 to 33.5) |
Urban | 7.85 (6.89 to 8.90) | 14.58 (12.90 to 16.42) | 16.4 (13.9 to 19.2) | 13.01 (11.80 to 14.33) | 21.51 (19.55 to 23.62) | 21.6 (18.7 to 24.8) | 10.48 (9.69 to 11.31) | 18.20 (17.00 to 19.45) | 19.0 (17.1 to 21.1) |
Total | 5.82 (5.24 to 6.45) | 14.60 (13.54 to 15.72) | 20.2 (18.4 to 22.3) | 9.15 (8.44 to 9.92) | 22.40 (21.17 to 23.66) | 31.1 (28.8 to 33.7) | 7.51 (7.04 to 8.00) | 18.60 (17.70 to 19.54) | 25.6 (24.1 to 27.2) |
HSV-2 incidence by age | |||
---|---|---|---|
Men | Women | Total | |
Age at baseline (years) | Incidence per 1000 person-years (95% CI) | Incidence per 1000 person-years (95% CI) | Incidence per 1000 person-years (95% CI) |
15–19 | 6.62 (4.36 to 9.63) | 12.12 (8.81 to 16.3) | 9.21 (7.19 to 11.62) |
20–24 | 10.30 (7.29 to 14.14) | 23.08 (18.59 to 28.34) | 16.91 (14.11 to 20.09) |
25–29 | 16.78 (12.77 to 21.64) | 24.63 (19.70 to 30.41) | 20.69 (17.46 to 24.34) |
30–34 | 25.10 (19.49 to 31.82) | 34.97 (28.42 to 42.58) | 30.15 (25.75 to 35.08) |
35–39 | 25.87 (20.21 to 32.63) | 44.85 (37.21 to 53.59) | 35.28 (30.47 to 40.64) |
40–44 | 31.70 (24.52 to 40.33) | 52.96 (43.94 to 63.28) | 42.82 (36.91 to 49.42) |
45–49 | 44.82 (36.26 to 54.79) | 46.89 (37.00 to 58.61) | 45.72 (39.14 to 53.09) |
Syphilis | |||||||||
---|---|---|---|---|---|---|---|---|---|
Men | Women | Total | |||||||
Baseline prevalence % (95% CI) | Follow-up prevalence % (95% CI) | Incidence per 1000 person-years (95% CI) | Baseline prevalence % (95% CI) | Follow-up prevalence % (95% CI) | Incidence per 1000 person-years (95% CI) | Baseline prevalence % (95% CI) | Follow-up prevalence % (95% CI) | Incidence per 1000 person-years (95% CI) | |
Rural | 1.75 (1.32 to 2.28) | 3.17 (2.48 to 3.99) | 3.85 (2.84 to 5.11) | 1.29 (0.93 to 1.75) | 2.63 (2.01 to 3.37) | 3.04 (2.16 to 4.16) | 1.52 (1.23 to 1.86) | 2.90 (2.43 to 3.42) | 3.44 (2.76 to 4.25) |
Urban | 2.55 (2.03 to 3.18) | 3.27 (2.50 to 4.20) | 2.45 (1.59 to 3.62) | 1.40 (1.02 to 1.88) | 2.31 (1.70 to 3.07) | 2.50 (1.67 to 3.61) | 1.97 (1.64 to 2.35) | 2.77 (2.28 to 3.33) | 2.48 (1.85 to 3.24) |
Total | 2.15 (1.80 to 2.55) | 3.22 (2.70 to 3.80) | 3.22 (2.53 to 4.05) | 1.35 (1.08 to 1.66) | 2.48 (2.04 to 2.98) | 2.79 (2.17 to 3.54) | 1.74 (1.52 to 1.99) | 2.84 (2.49 to 3.22) | 3.00 (2.52 to 3.54) |
Syphilis incidence by age | |||
---|---|---|---|
Men | Women | Total | |
Age at baseline (years) | Incidence per 1000 person-years (95% CI) | Incidence per 1000 person-years (95% CI) | Incidence per 1000 person-years (95% CI) |
15–19 | 0.94 (0.26 to 2.42) | 0.77 (0.16 to 2.26) | 0.86 (0.35 to 1.78) |
20–24 | 1.03 (0.28 to 2.65) | 1.37 (0.56 to 2.99) | 1.21 (0.58 to 2.23) |
25–29 | 1.88 (0.76 to 3.88) | 2.00 (0.86 to 3.93) | 1.94 (1.09 to 3.20) |
30–34 | 3.02 (1.38 to 5.72) | 3.47 (1.80 to 6.07) | 3.26 (2.02 to 4.99) |
35–39 | 5.61 (3.27 to 8.98) | 4.38 (2.45 to 7.22) | 4.96 (3.39 to 7.00) |
40–44 | 6.99 (3.99 to 11.35) | 4.91 (2.68 to 8.23) | 5.83 (3.94 to 8.33) |
45–49 | 6.33 (3.62 to 10.27) | 4.45 (2.03 to 8.45) | 5.49 (3.55 to 8.11) |